Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $2.91 in the first ...

Becton Dickinson and Company BDX, popularly known as BD, is scheduled to report first-quarter fiscal 2026 results on Feb. 9, ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025.

BDX Q1 FY2026 earnings call recap: strong results, Waters Life Sciences deal, $4B buybacks/debt paydown, and outlook amid tariffs.

Becton, Dickinson and CompanyBDX, popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System. Anticipated to ...

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination ...

BD (NYSE: BDX) today set the record date for the planned spin-off of its Biosciences & Diagnostics business to Waters ...

(RTTNews) - Becton, Dickinson and Co. (BDX) today announced that the U.S. FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, a next-generation device ...

State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026 FRANKLIN LAKES, N.J., Jan. 15, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a ...

BD (Becton, Dickinson and Company) has received 510(k) approval from the US Food and Drug Administration (FDA) for the EnCor EnCompass breast biopsy and tissue removal system. The approval marks the ...